Summit Therapeutics Inc
SMMT26.370USD
-0.290-1.09%
Handelsschluss 07/31, 16:00（ET）Kurse um 15 Minuten verzögert
19.56BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Summit Therapeutics Inc Unternehmen
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Unternehmensinformationen
BörsenkürzelSMMT
Name des UnternehmensSummit Therapeutics Inc
IPO-datumOct 14, 2004
Gegründet am2020
CEODr. Mahkam (Maky) Zanganeh
Anzahl der mitarbeiter159
WertpapierartOrdinary Share
GeschäftsjahresendeOct 14
Addresse601 Brickell Key Drive
StadtMIAMI
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl33131
Telefon13052032034
Websitehttps://www.smmttx.com/
BörsenkürzelSMMT
IPO-datumOct 14, 2004
Gegründet am2020
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.75M
+0.01%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.75M
+0.01%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Latin America
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Jul 29
Aktualisiert: Tue, Jul 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Duggan (Robert William)
74.83%
Zanganeh (Mahkam)
4.81%
Xia (Yu)
4.24%
Baker Bros. Advisors LP
3.29%
The Vanguard Group, Inc.
1.57%
Other
11.25%
Aktionäre
Aktionäre
Anteil
Duggan (Robert William)
74.83%
Zanganeh (Mahkam)
4.81%
Xia (Yu)
4.24%
Baker Bros. Advisors LP
3.29%
The Vanguard Group, Inc.
1.57%
Other
11.25%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
84.32%
Investment Advisor
6.66%
Hedge Fund
4.18%
Investment Advisor/Hedge Fund
2.38%
Research Firm
0.39%
Bank and Trust
0.07%
Pension Fund
0.02%
Sovereign Wealth Fund
0.01%
Other
1.96%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
428
726.72M
97.85%
-882.09K
2025Q1
437
723.14M
98.66%
+648.97K
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Duggan (Robert William)
555.75M
74.83%
+74.55K
+0.01%
May 30, 2025
Zanganeh (Mahkam)
35.74M
4.81%
+359.73K
+1.02%
Apr 15, 2025
Xia (Yu)
31.52M
4.24%
--
--
Apr 15, 2025
Baker Bros. Advisors LP
24.42M
3.29%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
1.57%
-30.07K
-0.26%
Mar 31, 2025
Fidelity Management & Research Company LLC
9.31M
1.25%
+1.29M
+16.12%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.51M
1.01%
-43.09K
-0.57%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.46M
0.87%
-11.97K
-0.19%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
0.65%
-751.52K
-13.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.28M
0.44%
+84.03K
+2.63%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Tema Oncology ETF
2.79%
ProShares Ultra Nasdaq Biotechnology
1.8%
Invesco Nasdaq Biotechnology ETF
1.51%
SPDR S&P Biotech ETF
1.11%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.64%
Direxion Daily S&P Biotech Bull 3X Shares
0.61%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0.23%
iShares Biotechnology ETF
0.22%
Mehr Anzeigen
Tema Oncology ETF
Anteil2.79%
ProShares Ultra Nasdaq Biotechnology
Anteil1.8%
Invesco Nasdaq Biotechnology ETF
Anteil1.51%
SPDR S&P Biotech ETF
Anteil1.11%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.99%
Invesco NASDAQ Next Gen 100 ETF
Anteil0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
Anteil0.64%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.61%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Anteil0.23%
iShares Biotechnology ETF
Anteil0.22%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
